Saturday, June 7, 2025 6/7/2025

Development of a laboratory XANES system for the analysis of metals in tissue for cancer research and chemotherapy drug development

Award Number: R44CA228912
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Development of a laboratory XANES system for the analysis of metals in tissue for cancer research and chemotherapy drug development - Project Summary/Abstract Due to recent major advances in understanding platinum chemotherapy drugs, which are used to treat an estimated 50-70% of cancer patients, a new frontier of metal-based anti-cancer drugs is emerging. Many promising novel metal-based drugs (e.g. Ru, Co, Au, Sn, etc.) and several new formulations of platinum prodrugs are now being investigated as replacements for conventional platinum therapies. These alternatives hold significant potential for overcoming the well-known disadvantages of current Pt-based chemotherapy, including the development of patient resistance and toxicity to non-tumorous tissue, including hair fall-out and damage to vital organs such as the kidney and brain. X-ray absorption near edge spectroscopy (XANES) is a powerful chemical analysis technique used to investigate the local atomic structure of these drugs. The electron structure of these new metal-based chemotherapy drugs is critical to their performance, including: intracellular activation in tumorous cells, transportation to the tumor, activity, and lifetime of the drug. However, these drugs exist in low concentrations in biological tissue and currently, XANES analysis requires researchers to travel to synchrotron light sources, which generate intense beams of x-rays but of which there are just a handful, as they cost $1B to build and ~$100M/year to operate. Synchrotron XANES systems are often extremely oversubscribed, with up to a 6-9-month application process and some beamlines limiting groups to a single run per year, all of which significantly limit access and the rate of research progress. We propose to develop a laboratory XANES system that utilizes a combination of breakthrough innovations to bring access to the capabilities of synchrotron-based XANES to laboratories worldwide. The system is expected to critically enable research in novel metal-based anti-cancer drugs, in addition to emerging research on the role of trace metal chemistry in pathologies including cancer. The proposed Phase I 6-month project is a proof-of-principle demonstration of the advantages stemming from the x-ray optic and geometry in a breadboard prototype. The proposed Phase II 24-month project is to develop a complete prototype.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2020	SIGRAY, INC.	5750 IMHOFF DR STE I	CONCORD	CA	94520	CONTRA COSTA	USA	Cancer Detection and Diagnosis Research	000	3	4/22/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $590,735 )
2020	2020	SIGRAY, INC.	5750 IMHOFF DR STE I	CONCORD	CA	94520	CONTRA COSTA	USA	Cancer Detection and Diagnosis Research	000	3	12/23/2019	NON-COMPETING CONTINUATION	$590,735
														Subtotal = $590,735

Issue Date FY: 2019 ( Subtotal = $875,336 )
2019	2019	SIGRAY, INC.	5750 IMHOFF DR STE I	CONCORD	CA	94520	CONTRA COSTA	USA	Cancer Detection and Diagnosis Research	001	2	12/31/2018	EXTENSION WITH OR WITHOUT FUNDS	$875,336
2019	2018	SIGRAY, INC.	5750 IMHOFF DR STE I	CONCORD	CA	94520	CONTRA COSTA	USA	Cancer Detection and Diagnosis Research	000	1	12/11/2018	NEW	$0
														Subtotal = $875,336

Issue Date FY: 2018 ( Subtotal = $224,989 )
2018	2018	SIGRAY, INC.	5750 IMHOFF DR STE I	CONCORD	CA	94520	CONTRA COSTA	USA	Cancer Detection and Diagnosis Research	000	1	4/4/2018	NEW	$224,989
														Subtotal = $224,989

Grand Total All Awards = $1,691,060

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of a laboratory XANES system for the analysis of metals in tissue for cancer research and chemotherapy drug development

Award Number: R44CA228912

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer